Qsymia

07/01/2015 - "Phase 3 clinical trial results reveal that Qsymia is a clinically effective long-term treatment for obesity, but whether this treatment is cost-effective compared to a diet and lifestyle intervention has yet to be explored. "
01/01/2014 - "Less than one month later, the FDA approved Qsymia for the treatment of obesity. "
09/01/2013 - "These 2 drugs, Belviq and Qsymia, have added new tools for the treatment of obesity. "
04/01/2013 - "Recently two new medications (Belviq and Qsymia) were approved by FDA for long-term management of obesity. "
01/01/2014 - "The FDA's risk/benefit calculus in the approvals of Qsymia and Belviq: treating an obesity epidemic while avoiding another fen-phen."

01/01/2018 - "While a prior case series exploring Qsymia for BED showed promise, randomized studies are needed to evaluate Qsymia's safety and efficacy when re-purposed in eating disorders. "

07/01/2015 - "Cost-Effectiveness Analysis of Qsymia for Weight Loss."
09/01/2014 - "Results suggest that, in the absence of other considerations and at current market prices, Weight Watchers and Qsymia represent the two most cost-effective strategies for nonsurgical weight loss."
03/01/2014 - "Phentermine/topiramate (Qsymia), available in the United States since September 2012, achieves clinically meaningful weight loss along with improvements in weight-related comorbidities. "
08/01/2013 - "Phentermine/topiramate extended-release capsules (Qsymia) for weight loss. "
08/01/2013 - "Phentermine/Topiramate extended-release capsules (qsymia) for weight loss."

12/01/2012 - "Mirabegron (Myrbetriq) for overactive bladder; phentermine/topiramate ER (Qsymia) for weight management; and ocriplasmin injection (Jetrea) for vitreomacular adhesion."

01/01/2014 - "The FDA's risk/benefit calculus in the approvals of Qsymia and Belviq: treating an obesity epidemic while avoiding another fen-phen."